Company intelligence / Profile preview
iCell Gene Therapeutics
Stony Brook, New York, United Statesicellgene.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
iCell’s cCAR platform has demonstrated durable medication-free remission in lupus patients for over four years. The company claims the largest public clinical database of CAR use in autoimmune diseases. Its anti-CD33/CLL1 compound CAR has shown efficacy in AML. Several publications support early clinical activity across multiple targets.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Chimeric Antigen Receptor T cells (CAR-T)Compound CARs (cCARs)CAR-NK cellsNon-gene edited universal CARs
- Industry
- Biotech
02
Drug pipeline
31 assets30 more assets in the full pipeline.
03
Partnerships
Indiana University listed as a collaborator/sponsor on some studiesAcademic collaborations with University of Virginia for GMP manufacturing facility validationNo major pharma partnerships publicly disclosed.
Beyond the preview
Go deeper on iCell Gene Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iCell Gene Therapeutics.